Shares of Sana Biotechnology, Inc. (SANA) plummeted 11.84% on Friday, as traders took profits following the stock's massive rally over the past week on upbeat clinical study results.
SANA's stock skyrocketed 151.5% in the past week after the company announced positive initial data from a first-in-human study of its experimental type 1 diabetes cell therapy, UP421. In the study, UP421 was transplanted into a patient without the need for immunosuppression, thanks to Sana's proprietary hypoimmune (HIP) technology.
The results showed survival and functionality of the transplanted pancreatic beta cells, demonstrated by the presence of C-peptide, a biomarker indicating insulin production. Crucially, no safety concerns were identified, and the HIP-modified cells evaded immune responses, eliminating the need for chronic immunosuppression.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。